| Spatial tumor immune microenvironment as a prognostic and predictive biomarker in anti-EGFR-based maintenance for RAS wt metastatic CRC - the PanaMa (AIO KRK0212) trial |
Ballhausen A |
Modest DP |
| Clin Cancer Res 31(19):4049-58 |
Vollpublikation |
2025 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
PanaMa |
AIO-KRK-0212 |
| doi.org/10.1158/1078-0432.CCR-25-0879 |
|
|
| Risk of disease progression in the first-line therapy of metastatic colorectal cancer to guide disease re-assessments - analysis of eleven trials by AIO and GONO. |
Germani MM |
Modest DP |
| Ann Oncol 36(11):1307-18 |
|
2025 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| doi.org/10.1016/j.annonc.2025.08.001 |
|
|
| Panitumumab plus 5-fluorouracil and folinic acid or 5-fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212): final efficacy analysis of a randomised, open-label, phase 2 trial. |
Stahler A |
Modest DP |
| eClinicalMedicine, Vol 79, 103004 |
Vollpublikation |
2025 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
PanaMa |
AIO-KRK-0212 |
| doi.org/10.1016/j.eclinm.2024.103004 |
|
|
| GOBLET study: Results of the Safety Run-in for First-line Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Patients Treated with Pelareorep + Modified FOLFIRINOX +/- Atezolizumab. |
Seufferlein T |
Heinemann V |
| J Clin Oncol 43 (no. 4_suppl): 730 |
Abstract |
2025 |
|
Kolon-/Rektum-/Dünndarmtumoren / Pankreaskarzinom
|
GOBLET |
AIO-KRK-PAK-0320/ass |
| doi.org/10.1200/JCO.2025.43.4_suppl.730 |
|
|
| GOBLET platform study: Preliminary Safety and Tumor Response Results for the Relapsed Anal Carcinoma Cohort in Patients Treated with Pelareorep and Atezolizumab. |
Modest DP |
Arnold D |
| Clin Oncol 43 (no. 4_suppl): 6. |
Abstract |
2025 |
|
Kolon-/Rektum-/Dünndarmtumoren / Pankreaskarzinom
|
GOBLET |
AIO-KRK-PAK-0320/ass |
| doi.org/10.1200/JCO.2025.43.4_suppl.6 |
|
|
| A phase III study testing the role of proactive coaching on patient reported outcome in advanced or metastatic renal cell carcinoma treated with sunitinib or a combination of axitinib + pembrolizumab or avelumab in first line therapy (PREPARE; AIO-NZK-0115/ass) |
Grünwald V |
Ivanyi P |
| J Clin Oncol 43 (no. 5_suppl): 523 |
Abstract |
2025 |
|
Nierenzellkarzinom
|
PREPARE |
AIO-NZK-0115/ass |
| doi.org/10.1200/JCO.2025.43.5_suppl.523 |
|
|
| Second-line therapy with Nal-IRI/5-FU/FA after failure of gemcitabine/nab-paclitaxel in advanced pancreatic cancer (PC): Predictive role of 1st-line therapy (PREDICT) and impact of quality of life (QoL). |
Karthaus M |
Lutz MP |
| J Clin Oncol 43 (no. 4_suppl): 707 |
Abstract |
2025 |
|
Pankreaskarzinom
|
PREDICT |
AIO-PAK-0216 |
| doi.org/10.1200/JCO.2025.43.4_suppl.707 |
|
|
| Corrigendum to "mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214) and the ABCSG (R-06)": [ESMO Open 9 (2024) 103703]. |
Hofheinz R |
Gaiser T |
|
Sonstige |
2025 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
AIO-KRK-0214 |
| doi.org/10.1016/j.esmoop.2024.104095 |
|
|
| Machine learning–based liquid biomarker analysis from the NEONAX trial for response prediction to perioperative (PO) and adjuvant (A) gemcitabine/nab-paclitaxel in resectable PDAC (rPDAC). |
Seufferlein T |
Ettrich T |
| J Clin Oncol 43 (no.4_suppl.): 755 |
Abstract |
2025 |
|
Pankreaskarzinom
|
NEONAX |
AIO-PAK-0313 |
| ascopubs.org/doi/10.1200/JCO.2025.43.4_suppl.75 |
|
|
| Prognostic and predictive impact of the baseline systemic proteome in patients with RAS wild-type metastatic colorectal cancer: Analysis from the randomized phase II PanaMa (AIO KRK0212) trial. |
Ballhausen A |
Modest D |
| J Clin Oncol 43 (no. 16_suppl): 3546 |
Abstract |
2025 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
PanaMa |
AIO-KRK-0212 |
| ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3546 |
|
|
